<DOC>
	<DOCNO>NCT00691301</DOCNO>
	<brief_summary>RATIONALE : Pemetrexed may stop growth tumor cell block enzymes need cell growth . Drugs use chemotherapy , cisplatin , work different way stop growth tumor cell , either kill cell stop divide . Giving pemetrexed together cisplatin may kill tumor cell . PURPOSE : This phase II trial study side effect give pemetrexed together cisplatin see well work treat patient advance , persistent , recurrent cervical cancer .</brief_summary>
	<brief_title>Pemetrexed Cisplatin Treating Patients With Advanced , Persistent , Recurrent Cervical Cancer</brief_title>
	<detailed_description>OBJECTIVES : Primary - To estimate antitumor activity pemetrexed disodium cisplatin objective tumor response ( partial complete response ) patient advance , persistent , recurrent carcinoma cervix . - To determine nature degree toxicity regimen patient . Secondary - To determine effect regimen progression-free survival overall survival . OUTLINE : This multicenter study . Patients stratify accord prior cisplatin therapy radiosensitizer ( yes v ) . Patients receive pemetrexed disodium IV 10 minute cisplatin IV 1-4 hour day 1 . Courses repeat every 21 day absence disease progression unacceptable toxicity . After completion study treatment , patient follow every 3 month 2 year every 6 month 3 year .</detailed_description>
	<mesh_term>Uterine Cervical Neoplasms</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Pemetrexed</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm squamous nonsquamous cell carcinoma cervix Advanced , persistent , recurrent disease Disease amenable curative therapy Measurable disease , define ≥ 1 unidimensionally measurable lesion ≥ 20 mm conventional technique ≥ 10 mm spiral CT scan Must ≥ 1 target lesion use assess response Tumors within previously irradiate field designate `` nontarget '' lesion unless progression document biopsy obtain confirm persistence ≥ 90 day follow completion radiotherapy PATIENT CHARACTERISTICS : GOG performance status 02 Platelet count ≥ 100,000/mm^3 ANC ≥ 1,500/mm^3 Bilirubin ≤ 1.5 time upper limit normal ( ULN ) Creatinine clearance ≥ 60 mL/min SGOT ≤ 2.5 time ULN ( ≤ 5 time ULN due hepatic metastasis ) Alkaline phosphatase ≤ 2.5 time ULN ( ≤ 5 time ULN due hepatic metastasis ) Negative pregnancy test Fertile patient must use effective contraception Neuropathy ( sensory motor ) ≤ grade 1 Able take folic acid , vitamin B12 , dexamethasone accord study protocol No history invasive malignancy within past 5 year , except nonmelanoma skin cancer No active infection require antibiotic exception uncomplicated UTI No presence third space fluid control drainage PRIOR CONCURRENT THERAPY : Recovered effect recent surgery , radiotherapy , therapy At least 1 week since prior hormonal therapy direct malignant tumor At least 4 week since prior radiotherapy More 3 year since prior radiotherapy localize cancer breast , head neck , skin patient remain free recurrent metastatic disease No prior radiotherapy portion abdominal cavity pelvis except treatment cervical cancer No prior radiotherapy 25 % marrowbearing area No prior cancer treatment contraindicate study treatment No prior cytotoxic drug advance recurrent carcinoma cervix Prior cisplatin radiosensitizer primary treatment disease allow No nonsteroidal antiinflammatory drug ( NSAIDs ) salicylates 25 day , , 2 day receive pemetrexed disodium No NSAIDS long halflife ( e.g. , naproxen , piroxicam , diflunisal , nabumetone ) 5 day , , 2 day receive pemetrexed disodium Concurrent hormone replacement therapy permit Concurrent daily lowdose acetylsalicylic acid therapy ( ≤ 325 mg/day ) allow Concurrent use acetylsalicylic acid ( 1.3 g/day ) allow</criteria>
	<gender>Female</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2015</verification_date>
	<keyword>cervical squamous cell carcinoma</keyword>
	<keyword>recurrent cervical cancer</keyword>
	<keyword>stage III cervical cancer</keyword>
	<keyword>stage IVA cervical cancer</keyword>
	<keyword>stage IVB cervical cancer</keyword>
</DOC>